This certification allows generic drug companies to challenge brand-name drug patents before expiration, seeking approval to market their generic version early. They declare the patent invalid, unenforceable, or not infringed. The brand-name manufacturer is notified and can initiate a patent infringement lawsuit within 45 days. If the court rules in favor of the generic company, it can obtain approval and enter the market before the patent's expiration, increasing competition.
Here's a step-by-step explanation of the process with an example:
1. ANDA Submission: Generic Drug Company (GDC) submits an ANDA to the FDA seeking approval for its generic version of Drug X, which is currently protected by a patent held by Brand Pharma (BP).
2. Patent Certification: GDC includes one of the following certifications in its ANDA application:
- Paragraph I (No patent information submitted)
- Paragraph II (Drug X's patents are expired)
- Paragraph III (GDC waits for the patent to expire before marketing the generic)
- Paragraph IV (Para IV certification challenging the patent)
3. Para IV Certification: GDC submits a Paragraph IV certification, asserting that BP's patent(s) covering Drug X is invalid, unenforceable, or not infringed upon by their generic version.
4. Notice Letter: The submission of a Para IV certification prompts the FDA to notify BP about the certification, including specific details about the patent(s) GDC is challenging.
5. Response by Brand Pharma: BP has 45 days from receiving the notice letter to file a patent infringement lawsuit against GDC. If BP doesn't file within this timeframe, GDC may receive a tentative approval for its generic drug.
6. Patent Litigation: If BP files a lawsuit, GDC may defend its Para IV certification in court, and the court will determine the validity of BP's patent(s). If the court rules in favor of GDC and finds the patent(s) invalid or not infringed upon, GDC can obtain final approval for its ANDA and market its generic drug.
Example: Let's say Brand Pharma holds a patent on Drug X, and it is set to expire in 2025. Generic Drug Company (GDC) decides to develop and market a generic version of Drug X before the patent expiration. GDC submits an ANDA with a Paragraph IV certification, claiming that BP's patent is invalid due to prior art that was not considered during the patent examination.
Upon receiving the notice of the Para IV certification, Brand Pharma analyzes GDC's claim and decides to sue GDC for patent infringement. The case goes to court, and after a thorough examination of evidence, the court rules in favor of GDC, finding BP's patent invalid due to the previously undisclosed prior art. As a result, GDC obtains final approval for its ANDA and can start selling its generic version of Drug X in the market before the patent's original expiration date, allowing patients to access more affordable medication options.
Post a Comment